HF Advisory Group LLC Sells 1,418 Shares of Pfizer Inc. (NYSE:PFE)

HF Advisory Group LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 1.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 88,486 shares of the biopharmaceutical company’s stock after selling 1,418 shares during the quarter. Pfizer comprises approximately 1.2% of HF Advisory Group LLC’s holdings, making the stock its 20th largest holding. HF Advisory Group LLC’s holdings in Pfizer were worth $2,561,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the business. Olistico Wealth LLC bought a new position in Pfizer in the second quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at $29,000. Quarry LP bought a new position in shares of Pfizer in the 2nd quarter worth $31,000. Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the 2nd quarter worth $34,000. Finally, ESL Trust Services LLC bought a new stake in Pfizer during the first quarter valued at about $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Citigroup started coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Stock Performance

Shares of PFE opened at $27.98 on Wednesday. The stock has a 50-day moving average of $28.99 and a two-hundred day moving average of $28.65. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a market cap of $158.55 billion, a P/E ratio of 37.81, a P/E/G ratio of 0.89 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.